Anti-Biofilm Wound Dressing Market Size, Share, and Trends 2024 to 2034

Anti-Biofilm Wound Dressing Market Size and Forecast 2024 to 2034

The global anti-biofilm wound dressing market size accounted for USD 874.74 million in 2024 and is expected to be worth around USD 1,941.62 million by 2034, at a CAGR of 8.3% from 2024 to 2034. Rising numbers of road accidents are observed to boost the growth of anti-biofilm wound dressing market.

Anti-Biofilm Wound Dressing Market Key Takeaways

• North America is predicted to grow at a CAGR of 9.9% from 2024 to 2034 and hold the maximum revenue share.
• The United Kingdom is projected to register growth at a CAGR of 9.1% from 2024 to 2034.
• Asia Pacific is considered the fastest-growing region between 2024 and 2034.
• By mode of mechanism, the chemical segment generated for more than 45% of the revenue share in 2023.
• By mode of mechanism, the biological segment is considered to boost at a remarkable CAGR from 2024 to 2034.
• By wound type, the chronic segment accounted for more than 60% of revenue share in 2023.
• By wound type, the acute segment is expected to grow at a remarkable CAGR rate between 2024 and 2034.
• By end-users, the hospital segment captured largest revenue share of approximately 45.50% in 2023.

Market Overview

The anti-biofilm wound dressing is an antimicrobial type of dressing used for patients with prolonged wounds comprised by the biofilm. A biofilm is a tough layer in an organic polymer matrix. Basically, a biofilm consists of microorganisms such as protozoa, bacteria and yeast. Biofilms produce destructive enzymes that adversely affect the pace of wound healing. 

The impaired healing of chronic or acute wounds is reformed or improved with the help of anti-biofilm agents. Poly hexamethylene biguanide, Cadexomor iodine, Poloxamer-based surfactant, wound gel and honey are a few significant anti-biofilm agents utilized to prevent the growth of biofilms and to clean the surface of wounds. 

The elimination of biofilms to boost the speed of wound healing was initially complex. The deployment of anti-biofilm agents in wound care management has helped the medicinal sector immensely. Anti-biofilms for wound dressing have the capacity to attack the biofilms without harming human tissues or cells. Companies involved in the global anti-biofilm wound dressing market are focused on developing an advanced anti-biofilm matrix, inventing effective cures for chronic wounds to enhance the survivability of patients and developing therapies for wound healing.

Anti-Biofilm Wound Dressing Market Growth Factors

Rising cases of sports injury, road accidents, diabetes and cancer patients across the globe are considered to boost the growth of the anti-biofilm wound dressing market. Along with this, rising government spending on the healthcare sector is projected to develop the market for anti-biofilm wound dressing. The rising development in the healthcare infrastructure in developing countries drives the growth of the anti-biofilm wound dressing market. The technological advancement for the development of an anti-biofilm matrix is another factor to propel the growth of the global anti-biofilm wound dressing market.  

The rising number of research and development (R&D) activities, along with the increasing investments in product development, are fueling the growth of the anti-biofilm wound dressing market. However, increased prices of wound care products are likely to hinder the global anti-biofilm wound dressing market growth. Moreover, factors such as the rising geriatric population and traumatic incidents are surging the demand for wound dressing services; this is projected to boost the development of the anti-biofilm wound dressing market.  

Market Scope

Market Dynamics

Driver

Rising sports injuries across the globe

Children are particularly at the edge of getting sports injuries. Stanford Children’s Health stated that approximately 3.5 million children are injured yearly during physical activity. Sports injuries often cause wounds on the lower body parts. However, such wounds can be easily treated with home care, but the risk of infection on the wound, such as discharge, swelling and pain, may lead to hospitalization. 

Wounds caused by sports injuries are considered in the acute wound category that heals within 2-3 weeks with a proper anti-biofilm wound dressing. With a rising number of sports activities, the probability of sports injuries increases.  

Restraint

Risks associated with the wound care treatment

The overall cost of wound care treatment has become high due to the increased prices of wound care materials. The fluctuation in prices of synthetic anti-biofilm agents in the market has impacted the prices of wound care products. Furthermore, the risks associated with wound care treatment limit the public acceptance of anti-biofilm wound dressing. 

An improper dressing or utilization of the wrong dressing product may lead to infection complications. In some cases, the lack of healing of wounds is directly associated with inappropriate wound dressing or wound care plans. Such risks associated with wound care treatment hinder the market’s growth.

Opportunity

Increasing volume of surgeries

In order to manage multiple health conditions, surgical procedures are increasing across the globe. Along with this, the availability of established healthcare infrastructure with advanced healthcare services has boosted the volume of surgeries. The rising number of surgeries offers a plethora of opportunities for the global anti-biofilm wound dressing market to grow. 

Every surgical procedure requires an incision to get access to the body tissue or organ, and such small or long incisions can cause surgical wounds. Thus, post-surgical wound care plays a vital role in the entire healthcare industry. 

Rising surgical activities offer lucrative opportunities for anti-biofilm wound dressing services, including wound protection, skin infection reduction, dressing for fluid loss, and covering surgical stitches. Along with the in-hospital wound care services, the growing number of post-acute care in the healthcare sector is offering opportunities for home-based wound care services globally.

Mode of Mechanism Insights

The chemical mode of mechanism segment holds approximately 45% of the market share, and it is anticipated to maintain growth during the forecast period. Chemical-based anti-bio wound dressing is considered ideal for both chronic and acute wounds. The chemical segment is further segmented into iodine silver, iodine, EDTA, and others. Chemical compounds are considered effective antiseptic agents for wound dressing. The low concentration of EDTA is capable of disrupting biofilms by inhibiting the adhesion of bacteria. Furthermore, iodine-based anti-biofilm wound dressing for severe burns. 

The biological segment is considered to boost at a significant rate during the forecast period. The biological segment is further segmented into dispersion B, lactoferrin, bacteriophage, and others. The bacteriophage segment has become a renewed interest for research in the global anti-biofilm wound dressing market.

Wound Type Insights

The chronic segment holds approximately 60% of the market share in the global anti-biofilm wound dressing market. The chronic segment is further segmented into applications for diabetic foot ulcers, pressure ulcers and venous leg ulcers. Chronic diseases such as diabetes often cause ulcers that are open and deep wounds, commonly on the bottom of the feet. The healing of such chronic wounds takes extended periods, or even a few won’t heal for a lifetime. For instance, approximately two million people in the United States suffer from diabetic foot ulcers. The rising cases of diabetes across the globe are considered to boost the growth of the chronic segment.

At the same time, the acute segment of wound type is projected to grow at a significant rate during the forecast period. The acute segment is further segmented into surgical wounds and burn wounds. A wide range of medical conditions require surgeries, surgical wounds are caused during surgical procedures while making incisions, and such wounds are healed quickly within 3-4 weeks without a complex dressing procedure. According to the World Health Organization (WHO), India registers approximately 1,00,000 cases of burns each year; this rising number will promote the acute segment in the global anti-biofilm wound dressing market.  

End-User Insights

The hospital segment holds the largest revenue share of approximately 45.50% in the global anti-biofilm wound dressing market. The rising number of hospital admissions for surgery is a significant factor in boosting the growth of the hospital segment in the global anti-biofilm wound dressing market. The availability of advanced wound treatment procedures and long-term care options for wound healing have fueled the segment's growth. Moreover, sports injuries in kids are the most common factor for hospital admissions, the rising number of sports injuries is considered to boost the growth of hospital segment.

The home care segment is predicted to witness a significant increase during the forecast period. The outbreak of Coronavirus in 2020 forced the population to adopt home care wound dressing services. The advantages of home care, such as rapid healing, reduced risk of infection, familiar surroundings, home nursing facility and personalized healthcare service, are boosting the inclination of patients towards the home care segment.

Regional Insights

North America is expected to grow at a CAGR of 9.9% during the forecast period, with the largest revenue share in the global anti-biofilm wound dressing market. The presence of advanced medical services and major key players in the region are seen as significant factors boosting the market's growth. Moreover, the rising prevalence of diabetes in the region is expected to increase the demand for amputation surgeries; this will subsequently fuel the market for anti-biofilm wound dressing. Along with this, the rising geriatric population in the region is supporting the market’s growth.  

The United Kingdom is expected to register growth at a CAGR of 9.1% during the forecast period in the anti-biofilm wound dressing market. Europe holds a significant share of the global anti-biofilm wound dressing market. The rising cases of diabetic ulcers and sports injuries are estimated to boost the market’s growth in Europe during the forecast period. Furthermore, the presence of well-established healthcare infrastructure has allowed the rapid adoption of advanced wound care management services in the region.  

Asia Pacific is considered the fastest-growing region in the global anti-biofilm wound dressing market. Improving healthcare infrastructure is believed to boost the market’s growth during the forecast timeframe. The rising number of wound care centers in India and China is propelling the development of the anti-biofilm wound dressing market. China is focused on setting up advanced wound care management centers in the country's major cities; this promises substantial growth for the anti-biofilm wound dressing market in Asia Pacific.  

Anti-Biofilm Wound Dressing Market Companies

• Conva-Tec
• Smith & Nephew Plc
• Coloplast 
• 3M
• Urgo Medical
• Imbed Biosciences
• Lohmann & Rauscher

Recent Developments

• In February 2023, the United States-based Vista Health Systems announced the opening of Vista Wound Care Services in Waukegan, Illinois. Vista Wound Care Services Center aims to provide leading-edge treatment for chronic and acute wounds that can prevent infection and reduce the risk of tissue loss and amputations. Vista will offer services in Waukegan and surrounding cities. 
• In January 2023, a researchers’ team at the University of Newcastle announced that they have entered into a partnership with Hunter-based therapeutics goods manufacturer Whiteley Corporation to develop advanced treatments for chronic wounds. The outcomes of this partnership will deliver a potential medical improvement in Australia and worldwide. This collaboration aims to work on a combination of treatments that include wound debridement, wound mapping and anti-biofilm therapy.  
• In January 2023, Ampcontrol announced the partnership with Whiteley Corporation for chronic wound research. Ampcontrol is an electrical engineering company that has recently received a grant from the federal government’s Cooperative Research Centers Program worth $5.6 million for a period of three years. The collaborative team aims to create a singular treatment for wound care. 
• In January 2023, PhaseOne Health announced the expansion of its commercial program for the wound care market by formulating a collaborative partnership with NovaBay, an innovative wound dressing manufacturer in the United States. 
• In October 2022, a biotech company developing targeted immune-enabling biologic therapies to counter infection with biofilms, Clarametyx Biosciences, Inc, announced the acceptance of the company’s Investigational New Drug Application (IND) by the U.S. Food & Drug Administration (FDA). Clarametyx Biosciences can now initiate a first in human phase study.  
• In March 2022, the United Kingdom-based ConvaTec Inc announced the acquisition of Triad Life Sciences Inc for $450 million. The strategic acquisition aims to strengthen ConvaTec’s portfolio of biomedical products for surgical and chronic wounds.  
• In April 2021, Imbed Inc announced the clearance of antimicrobial matrix products by the U.S. Food and Drug Administration (FDA). The antimicrobial matrix products developed by Imbed Inc are effective solutions for numerous medical conditions and can be used in treating surgical or traumatic wounds.  

Segments Covered in the Report

By Mode of Mechanism

• Physical
• Chemical
• Biological

By Wound Type

• Acute wounds
• Chronic wounds

By End-Users

• Hospitals
• Specialty clinics
• Home healthcare

By Geography

• North America
• Europe
• Asia-Pacific
• Latin America
• The Middle East and Africa